US 2023/0265141 A1 · PREPARATION METHOD AND USE OF DOUBLE-TARGET FUSION PROTEIN

Abstract

The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

Claims3

Dependent claims

A fusion protein, comprising R1-R2 or R1-L-R2,

wherein R1 is a human fibroblast growth factor FGF19 protein, R2 is a glucagon-like peptide-1, and L is a linker peptide;
and
the FGF19 protein has the amino acid sequence as set forth in any one of SEQ ID NO. 1-3;
and the glucagon-like peptide 1 has the amino acid sequence as set forth in SEQ ID NO. 4.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

18/181,666Filed 10 Mar 2023

Priority

CN 202110499380.830 Apr 2021

Published

24 Aug 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/50
Growth factors; Growth regulators: fibroblast growth factor [FGF]
A61K 38/1825
Growth factors; Growth regulators: fibroblast growth factor [FGF]
A61K 38/26
Hormones: glucagons
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents

Preparation method and use of double-target fusion protein

Life of this patent

Preparation method and use of double-target fusion protein

Life of this patent

Abstract

Claims3